Xiuning Le: Phase 2 RAMOSE osimertinib with or without ramucrimab in 1L EGFR+ NSCLC

Xiuning Le shared a post on X:

“Newly online Journal of Clinical Oncology. Our randomized phase 2 RAMOSE osimertinib +/- ramucrimab in 1L EGFR+ NSCLC. In the 139 patients, mPFS 24.8 vs. 15.6 months (HR0.55, p=0.023). G3 TRAEs 53% vs. 41%.”

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)

Authors: : Xiuning Le, et al.

Xiuning Le, MD, serves as the Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, where she oversees clinical research, including strategic planning and the operation of clinical trials within the department. She is also an Associate Professor and a leading translational researcher, specializing in resistance mechanisms, cancer genetics and genomics, biomarkers, and radiomics.